In the third podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Mark McKenna, CEO of Mirador Therapeutics.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart
On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McKenna, CEO of Mirador Therapeutics, a member of BioSpace’s NextGen Class of 2025. Their discussion here focused on the company’s two-pronged approach to developing therapies for inflammatory and fibrotic diseases, as well as the importance of operating under stealth at this time for the biotech.
This is the third episode in a special series of The Weekly focused on how NextGen companies are navigating the current business environment.
Host
Annalee Armstrong, Senior Editor, BioSpace
Guest
Mark McKenna, CEO of Mirador Therapeutics
For a complete list of NextGen 2025 companies, click here.
The NextGen Class of 2025 is brought to you by Pliancy.
